Toll样受体信号通路在宫颈高危HPV感染致癌过程中的相关功能

摘要/Abstract

摘要：Toll样受体(TLR)是最特征性的病原模式识别受体，在宫颈人乳头瘤病毒(HPV)感染的过程中，TLR信号通路影响了HPV感染的转归，在宫颈高危HPV感染至宫颈癌变的进程中起到促进或抑制肿瘤的免疫调节作用。TLR的基因多态性与宫颈癌的发生也密切相关。

徐小仙, 楼寒梅. Toll样受体信号通路在宫颈高危HPV感染致癌过程中的相关功能[J]. 国际肿瘤学杂志, 2014, 41(11): 840-843.

XU Xiao-Xian, LOU Han-Mei. Function of Toll like receptor signaling pathway in the carcinogenesis process related to high risk HPV infection of cervical[J]. Journal of International Oncology, 2014, 41(11): 840-843.

参考文献

［1］ Kumar H， Kawai T， Akira S. Tolllike receptors and innate immunity［J］. Biochem Biophys Res Commun，2009，388(4): 621625. ［2］ Huang B， Zhao J， Li H， et al. Tolllike receptors on tumor cells facilitate evasion of immune surveillance［J］. Cancer Res， 2005， 65（12）:50095014. ［3］ CherfilsVicini J， Platonova S， Gillard M， et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance［J］. J Clin Invest， 2010， 120(4):12851297. ［4］ Lee JW， Choi JJ， Seo ES， et al. Increased tolllike receptor 9 expression in cervical neoplasia［J］. Mol Carcinog， 2007， 46（11）:941947. ［5］ Kim WY， Lee JW， Choi JJ， et al. Increased expression of Tolllike receptor 5 during progression of cervical neoplasia［J］. Int J Gynecol Cancer， 2008， 18（2）:300305. ［6］ Huang B， Zhao J， Unkeless JC， et al. TLR signaling by tumor and immune cells: a doubleedged sword［J］. Oncogene， 2008， 27(2):218224. ［7］ Bucala R. Macrophage migration inhibitory factor: a probable link between inflammation and cancer［J］. Immunity， 2007， 26（3）:281285. ［8］ Phan RT, DallaFavera R. The BCL6 protooncogene suppresses p53 expression in germinalcentre B cells［J］. Nature, 2004,432(7017): 635639. ［9］ Schmausser B, Andrulis M, Endrich S, et al. Tolllike receptors TLR4, TLR5 andTLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori［J］. Int J Med Microbiol, 2005, 295(2):179185. ［10］ Fukata M, Chen A, Vamadevan AS, et al. Tolllike receptor4 promotes the development of colitisassociated colorectal tumors［J］. Gastroenterology, 2007, 133(6):18691881. ［11］ Yu L, Wang L, Chen S. Dual character of Tolllike receptor signaling:protumorigenic effects and antitumor functions［J］. Biochim Biophys Acta, 2013, 1835(2):144154. ［12］ Daud II, Scott ME, Ma Y, et al. Association between tolllike receptor expression and human papillomavirus type 16 persistence［J］. Int J Cancer, 2011, 128(4):879886. ［13］ Yu L, Wang L, Li M, et al. Expression of tolllike receptor 4 is downregulated during progression of cervical neoplasia［J］. Cancer Immunol Immunother, 2010, 59(7):10211028. ［14］ Werner J, DeCarlo CA, Escott N, et al. Expression of integrins and Tolllike receptors in cervical cancer: Effect of infectious agents［J］. Innate Immunity, 2011, 18(1):5569. ［15］ Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer associated human papillomavirus type 16［J］. J Immunol, 2007, 178(5):31863197. ［16］ Huang CY, Chen JJW, Shen KY, et al. Recombinant lipidated HPV E7 induces a Th1biased immune response and protective immunity against cervical cancer in a mouse model［J］. PLoS One, 2012, 7(7):e40970. ［17］ Idoyaga J, Moreno J, Bonifaz L. Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands［J］. Cancer Immunol Immunother, 2007, 56(8):12371250. ［18］ Yang R, Murillo FM, Delannoy MJ, et al. B lymphocyte activation by human papillomaviruslike particles directly induces Ig class switch recombination via TLR4MyD88［J］. J Immunol, 2005, 174(12): 79127919. ［19］ Xu Y, Hu Y, Shi B, et al. HBsAg inhibits TLR9mediated activation and IFNalpha production in plasmacytoid dendritic cells［J］. Mol Immunol, 2009, 46(13):26402646. ［20］ Xie Q, Shen HC, Jia NN, et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9［J］. Microbes Infect, 2009, 11（4）：515523. ［21］ Shiina M, Rehermann B. Cell cultureproduced hepatitis C virus impairs lasmacytoid dendritic cell function［J］. Hepatology, 2008, 47(2):385395. ［22］ Hirsch I, Caux C, Hasan U, et al. Impaired Tolllike receptor 7 and 9 signaling :from chronic viral infections to cancer［J］. Trends Immunol, 2010, 31(10):391397. ［23］ Roszak A, Lianeri M, Sowińska A，et al. Involvement of Tolllike Receptor 9 polymorphism in cervical cancer development［J］. Mol Biol Rep, 2012, 39(8):84258430. ［24］ Pandey S, Mittal RD, Srivastava M, et al. Impact of Tolllike receptors ［TLR］2 (196 to 174 del) and TLR 4 (Asp299Gly,Thr399Ile) in cervical cancer susceptibility in North Indian women［J］. Gynecol Oncol, 2009, 114（3）:501505. ［25］ Bodelon C, Madeleine MM, Johnson LG, et al. Genetic variation in the TLR and NFκB pathways and cervical and vulvar cancer risk: A populationbased casecontrol study［J］. Int J Cancer, 2014, 134(2):437444.

[1]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[2]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英.免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[3]	吕璐, 孙鹏飞.肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[4]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏.复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[5]	马雪艳, 鲁历历, 孙鹏飞.免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[6]	张露, 周菊英, 马辰莺, 林州.复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[7]	史英侠, 胡莉钧, 于静萍.免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.
[8]	彭琛, 谢印通, 张昕, 谢鹏.宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[9]	熊婵, 阎英, 谢晓冬, 孟繁杰, 于卉影.辐射诱导的多倍体宫颈癌HeLa细胞生物学特性研究[J]. 国际肿瘤学杂志, 2022, 49(5): 263-269.
[10]	袁晨阳, 周菊英.宫颈癌预后因素的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 307-313.
[11]	袁晨阳, 周菊英, 杜霄, 纪环, 赵天翼.宫颈癌2018与2009 FIGO分期的比较及预后因素分析[J]. 国际肿瘤学杂志, 2022, 49(3): 151-163.
[12]	王玥, 吴琼, 许愿, 龚唯, 徐晓婷.老年宫颈癌的筛查与治疗进展[J]. 国际肿瘤学杂志, 2022, 49(12): 754-758.
[13]	马秀珍, 卢艳, 赵冰冰, 邱宏聪, 徐勋, 韦敏.岗松总黄酮对宫颈癌SiHa细胞迁移、侵袭及凋亡的影响[J]. 国际肿瘤学杂志, 2021, 48(4): 206-211.
[14]	牛雯娟, 段文杰, 苏雅婷, 魏芳.对2018年国际妇产联盟宫颈癌新分期的思考[J]. 国际肿瘤学杂志, 2021, 48(10): 627-630.
[15]	于明月, 陈峥峥, 赵旭旭, 任萍萍, 张影, 葛丽, 朱美玲, 赵卫东.局部晚期宫颈癌术后辅助治疗的影响因素及其列线图风险模型的构建[J]. 国际肿瘤学杂志, 2021, 48(1): 35-40.